Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 81.55

-2.0%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	3/1/2011 2:31:14 PM
	of 4676

Barclays Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); 4Q10 Update - Mipomersen Filings on Track Barclays maintains an 'Overweight' on ISIS Pharmaceuticals (NASDAQ: ISIS), PT $17. Barclays analyst says, "While most of the focus remains on lipid-lowering drug mipomersen, we believe ISIS provides further upside potential with a deep and expanding pipeline of antisense drug candidates, multiple partnerships and a strong balance sheet." (Barclays raises FY11 EPS estimate from -0.62 to -0.56)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next